Is abnormal axonal transport a cause, a contributing factor or a consequence of the neuronal pathology in Alzheimer's disease?

Future Neurology

Volumn 4, Issue 6, 2009, Pages 761-773

  Muresan, Virgil ^a   Muresan, Zoia ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Alzheimer's disease; Amyloid peptide; Amyloid precursor protein; Apolipoprotein E4; Axonal transport; JNK interacting protein 1; Kinesin; Neurodegeneration; Presenilin 1; Sortilin related receptor

Indexed keywords

AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E4; KINESIN 1; NEUROPEPTIDE RECEPTOR; PRESENILIN 1; SORTILIN RELATED RECEPTOR; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; COGNITIVE DEFECT; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HUMAN; MEMORY DISORDER; NERVE DEGENERATION; NERVE FIBER TRANSPORT; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN SYNTHESIS; PROTEIN TARGETING; PROTEIN TRANSPORT; REVIEW; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION;

EID: 75249090200     PISSN: 14796708     EISSN: None     Source Type: Journal    
DOI: 10.2217/fnl.09.54     Document Type: Review

References (118)

1. Goedert M, Spillantini MG: A century of Alzheimer's disease. Science 314, 777-781 (2006).
2. Selkoe DJ: Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81, 741-766 (2001).
3. Sisodia SS: Alzheimer's disease: perspectives for the new millennium. J. Clin. Invest. 104, 1169-1170 (1999).
4. Selkoe DJ: Translating cell biology into therapeutic advances in Alzheimer's disease. Nature 399, A23-A31 (1999).
5. Hedera P, Turner RS: Inherited dementias. Neurol. Clin. 20, 779-808, vii (2002).
6. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE: Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat. Genet. 39, 17-23 (2007).
7. Bertram L, Tanzi RE: Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat. Rev. Neurosci. 9, 768-778 (2008).
8. Gotz J, Ittner LM: Animal models of Alzheimer's disease and frontotemporal dementia. Nat. Rev. Neurosci. 9, 532-544 (2008).
9. Sisodia SS, St George-Hyslop PH: γ-Secretase, Notch, Aβ and Alzheimer's disease: where do the presenilins fit in? Nat. Rev. Neurosci. 3, 281-290 (2002).
10. Tanzi RE: A genetic dichotomy model for the inheritance of Alzheimer's disease and common age-related disorders. J. Clin. Invest. 104, 1175-1179 (1999).
11. Bales KR, Verina T, Dodel RC et al.: Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition. Nat. Genet. 17, 263-264 (1997).
12. Farrer LA, Cupples LA, Haines JL et al.: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 278, 1349-1356 (1997).
13. Saunders AM, Strittmatter WJ, Schmechel D et al.: Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43, 1467-1472 (1993).
14. Haass C, Selkoe DJ: Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat. Rev. Mol. Cell Biol. 8, 101-112 (2007).
15. Selkoe DJ: Alzheimer's disease is a synaptic failure. Science 298, 789-791 (2002).
16. Frolkis VV, Tanin SA, Gorban YN: Age-related changes in axonal transport. Exp. Gerontol. 32, 441-450 (1997).
17. Minoshima S, Cross D: In vivo imaging of axonal transport using MRI: aging and Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging 35(Suppl. 1), S89-S92 (2008).
18. Smith KD, Kallhoff V, Zheng H, Pautler RG: In vivo axonal transport rates decrease in a mouse model of Alzheimer's disease. Neuroimage 35, 1401-1408 (2007).
19. Muresan V: One axon, many kinesins: what's the logic? J. Neurocytol. 29, 799-818 (2000).
20. Adalbert R, Nogradi A, Babetto E et al.: Severely dystrophic axons at amyloid plaques remain continuous and connected to viable cell bodies. Brain 132, 402-416 (2009). ■ Example of a careful and rigorous analysis of axonal pathology, using a combination of in situ imaging, electron microscopy and immunohistochemistry techniques.
21. Boutajangout A, Authelet M, Blanchard V et al.: Characterisation of cytoskeletal abnormalities in mice transgenic for wild-type human tau and familial Alzheimer's disease mutants of APP and presenilin-1. Neurobiol. Dis. 15, 47-60 (2004).
22. Stokin GB, Lillo C, Falzone TL et al.: Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 307, 1282-1288 (2005). ■■ Demonstrates that axonal defects consistent with impaired axonal transport are detected in the early stages of Alzheimer's disease in humans, and in mouse models of Alzheimer's disease, where they precede known disease-related pathology. The study also shows that the experimental impairment of axonal transport in transgenic mice causes axonal defects, increased amyloid-β (Aβ) levels and amyloid deposition, proving that axonal transport deficiencies can trigger the development of lesions typical for Alzheimer's disease.
23. Adalbert R, Gilley J, Coleman MP: Aβ, tau and ApoE4 in Alzheimer's disease: the axonal connection. Trends Mol. Med. 13, 135-142 (2007).
24. Roy S, Zhang B, Lee VM, Trojanowski JQ: Axonal transport defects: a common theme in neurodegenerative diseases. Acta Neuropathol. (Berl.) 109, 5-13 (2005).
25. Stokin GB, Goldstein LS: Axonal transport and Alzheimer's disease. Annu. Rev. Biochem. 75, 607-627 (2006).
26. Kamal A, Almenar-Queralt A, LeBlanc JF, Roberts EA, Goldstein LSB: Kinesin-mediated axonal transport of a membrane compartment containing βs-secretase and presenilin-1 requires APP. Nature 414, 643-648 (2001).
27. Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH: Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature 405, 360-364 (2000).
28. Matsuo ES, Shin RW, Billingsley ML et al.: Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. Neuron 13, 989-1002 (1994).
29. Lee MS, Kao SC, Lemere CA et al.: APP processing is regulated by cytoplasmic phosphorylation. J. Cell Biol. 163, 83-95 (2003).
30. Perlson E, Jeong GB, Ross JL et al.: A switch in retrograde signaling from survival to stress in rapid-onset neurodegeneration. J. Neurosci. 29, 9903-9917 (2009).
31. Moreno H, Yu E, Pigino G et al.: Synaptic transmission block by presynaptic injection of oligomeric amyloid β. Proc. Natl Acad. Sci. USA 106, 5901-5906 (2009).
32. Lin MT, Beal MF: Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443, 787-795 (2006).
33. Kamal A, Stokin GB, Yang Z, Xia C, Goldstein LS: Axonal transport of amyloid precursor protein is mediated by direct binding to the kinesin light chain subunit of kinesin-I. Neuron 28, 449-459 (2000).
34. Goldstein L, Almenar A, Kamal A, Stokin G: Letter to the Editor. J. Neurosci. 25 (2005).
35. Lazarov O, Morfini GA, Lee EB et al.: Axonal transport, amyloid precursor protein, kinesin-1, and the processing apparatus: revisited. J. Neurosci. 25, 2386-2395 (2005).
36. Selkoe DJ: The cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease. Trends Cell Biol. 8, 447-453 (1998).
37. Selkoe DJ: Cell biology of the amyloid β-protein precursor and the mechanism of Alzheimer's disease. Annu. Rev. Cell Biol. 10, 373-403 (1994).
38. Sisodia SS: β-amyloid precursor protein cleavage by a membrane-bound protease. Proc. Natl Acad. Sci. USA 89, 6075-6079 (1992).
39. Sisodia SS, Annaert W, Kim SH, De Strooper B: γ-secretase: never more enigmatic. Trends Neurosci. 24, S2-S6 (2001).
40. Gunawardena S, Goldstein LS: Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila. Neuron 32, 389-401 (2001).
41. Goldsbury C, Mocanu MM, Thies E et al.: Inhibition of APP trafficking by tau protein does not increase the generation of amyloid-β peptides. Traffic 7, 873-888 (2006).
42. Sisodia SS: Biomedicine. A cargo receptor mystery APParently solved? Science 295, 805-807 (2002).
43. Amaratunga A, Leeman SE, Kosik KS, Fine RE: Inhibition of kinesin synthesis in vivo inhibits the rapid transport of representative proteins for three transport vesicle classes into the axon. J. Neurochem. 64, 2374-2376 (1995).
44. Ferreira A, Niclas J, Vale RD, Banker G, Kosik KS: Suppression of kinesin expression in cultured hippocampal neurons using antisense oligonucleotides. J. Cell Biol. 117, 595-606 (1992).
45. Ferreira A, Caceres A, Kosik KS: Intraneuronal compartments of the amyloid precursor protein. J. Neurosci. 13, 3112-3123 (1993).
46. Kaether C, Skehel P, Dotti CG: Axonal membrane proteins are transported in distinct carriers: a two-color video microscopy study in cultured hippocampal neurons. Mol. Biol. Cell 11, 1213-1224 (2000).
47. Yamazaki T, Selkoe DJ, Koo EH: Trafficking of cell surface β-amyloid precursor protein: retrograde and transcytotic transport in cultured neurons. J. Cell Biol. 129, 431-442 (1995).
48. Inomata H, Nakamura Y, Hayakawa A et al.: A scaffold protein JIP-1β enhances amyloid precursor protein phosphorylation by JNK and its association with kinesin light chain 1. J. Biol. Chem. 278, 22946-22955 (2003). ■ Demonstrates that JNK-interacting protein-1 enhances the interaction of amyloid precursor protein (APP) with the light chains of kinesin-1, thus providing the proof-of-principle that JIP-1 could mediate the interaction of APP with kinesin-1.
49. Matsuda S, Matsuda Y, D'Adamio L: Amyloid-β protein precursor (AbPP), but not AbPP-like protein 2, is bridged to the kinesin light chain by the scaffold protein JNK-interacting protein 1. J. Biol. Chem. 278, 38601-38606 (2003). ■ Demonstrates that the interaction of APP with the light chains of kinesin-1 is not direct, but is mediated by JIP-1.
50. Muresan Z, Muresan V: Coordinated transport of phosphorylated amyloid-β precursor protein and c-Jun NH2-terminal kinase-interacting protein-1. J. Cell Biol. 171, 615-625 (2005). ■ Demonstrates that transport of APP into neurites occurs via several pathways, which use distinct vesicle populations that recruit the kinesin-1 motor by different mechanisms. The study also shows that, under normal conditions, only the phosphorylated APP recruits kinesin-1 via JIP-1, to be transported to neurite terminals.
51. Matsuda S, Yasukawa T, Homma Y et al.: c-Jun N-terminal kinase (JNK)-interacting protein-1b/islet-brain-1 scaffolds Alzheimer's amyloid precursor protein with JNK. J. Neurosci. 21, 6597-6607 (2001).
52. Scheinfeld MH, Roncarati R, Vito P, Lopez PA, Abdallah M, D'Adamio L: Jun NH2-terminal kinase (JNK) interacting protein 1 (JIP1) binds the cytoplasmic domain of the Alzheimer's β-amyloid precursor protein (APP). J. Biol. Chem. 277, 3767-3775 (2002).
53. Taru H, Iijima K, Hase M, Kirino Y, Yagi Y, Suzuki T: Interaction of Alzheimer's β-amyloid precursor family proteins with scaffold proteins of the JNK signaling cascade. J. Biol. Chem. 277, 20070-20078 (2002).
54. Verhey KJ, Meyer D, Deehan R et al.: Cargo of kinesin identified as JIP scaffolding proteins and associated signaling molecules. J. Cell Biol. 152, 959-970 (2001).
55. Whitmarsh AJ, Kuan CY, Kennedy NJ et al.: Requirement of the JIP1 scaffold protein for stress-induced JNK activation. Genes Dev. 15, 2421-2432 (2001).
56. Muresan Z, Muresan V: c-Jun NH2-terminal kinase-interacting protein-3 facilitates phosphorylation and controls localization of amyloid-β precursor protein. J. Neurosci. 25, 3741-3751 (2005).
57. Suzuki T, Oishi M, Marshak DR, Czernik AJ, Nairn AC, Greengard P: Cell cycle-dependent regulation of the phosphorylation and metabolism of the Alzheimer amyloid precursor protein. EMBO J. 13, 1114-1122 (1994).
58. Borg JP, Ooi J, Levy E, Margolis B: The phosphotyrosine interaction domains of X11 and FE65 bind to distinct sites on the YENPTY motif of amyloid precursor protein. Mol. Cell Biol. 16, 6229-6241 (1996).
59. Radzimanowski J, Simon B, Sattler M, Beyreuther K, Sinning I, Wild K: Structure of the intracellular domain of the amyloid precursor protein in complex with Fe65-PTB2. EMBO Rep. 9, 1134-1140 (2008).
60. Setou M, Nakagawa T, Seog DH, Hirokawa N: Kinesin superfamily motor protein KIF17 and mLin-10 in NMDA receptor- containing vesicle transport. Science 288, 1796-1802 (2000).
61. Muresan V, Varvel NH, Lamb BT, Muresan Z: The cleavage products of amyloid-β precursor protein are sorted to distinct carrier vesicles that are independently transported within neurites. J. Neurosci. 29, 3565-3578 (2009). ■ Demonstrates that axonal transport of APP mostly occurs after its cleavage into functional polypeptides, and that these polypeptides are sorted into separate cargo vesicles that are independently transported by kinesin-1 on distinct microtubule tracks to different destination within the neurites.
62. Muresan Z, Muresan V: A phosphorylated, carboxy-terminal fragment of β-amyloid precursor protein localizes to the splicing factor compartment. Hum. Mol. Genet. 13, 475-488 (2004).
63. Salehi A, Delcroix JD, Belichenko PV et al.: Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 51, 29-42 (2006). ■ Demonstrates that increased expression of APP in transgenic mice leads to decreased axonal transport of select proteins, via a mechanism that likely does not involve Aβ.
64. Stokin GB, Almenar-Queralt A, Gunawardena S et al.: Amyloid precursor protein-induced axonopathies are independent of amyloid-β peptides. Hum. Mol. Genet. 17, 3474-3486 (2008).
65. LaFerla FM, Green KN, Oddo S: Intracellular amyloid-β in Alzheimer's disease. Nat. Rev. Neurosci. 8, 499-509 (2007).
66. Kasa P, Papp H, Kovacs I, Forgon M, Penke B, Yamaguchi H: Human amyloid-β1-42 applied in vivo inhibits the fast axonal transport of proteins in the sciatic nerve of rat. Neurosci. Lett. 278, 117-119 (2000).
67. Hiruma H, Katakura T, Takahashi S, Ichikawa T, Kawakami T: Glutamate and amyloid β-protein rapidly inhibit fast axonal transport in cultured rat hippocampal neurons by different mechanisms. J. Neurosci. 23, 8967-8977 (2003).
68. Rui Y, Tiwari P, Xie Z, Zheng JQ: Acute impairment of mitochondrial trafficking by β-amyloid peptides in hippocampal neurons. J. Neurosci. 26, 10480-10487 (2006). ■ Demonstrates that exposure of hippocampal neurons to Aβ causes acute inhibition of mitochondrial transport, via a signaling pathway involving protein kinase A and glycogen synthase kinase 3β.
69. Pigino G, Morfini G, Atagi Y et al.: Disruption of fast axonal transport is a pathogenic mechanism for intraneuronal amyloid-β. Proc. Natl Acad. Sci. USA 106, 5907-5912 (2009). ■ Demonstrates that perfusion of squid axoplasm with Aβ oligomers causes inhibition of bidirectional axonal transport. This inhibition occurs through activation of casein kinase 2, which leads to the phosphorylation of the light chains of kinesin-1 and release of the motor from its cargoes.
70. Muresan V, Muresan Z: No conventional function for the conventional kinesin? Traffic 9, 1823-1827 (2008).
71. Takahashi RH, Almeida CG, Kearney PF et al.: Oligomerization of Alzheimer's β-amyloid within processes and synapses of cultured neurons and brain. J. Neurosci. 24, 3592-3599 (2004).
72. Muresan Z, Muresan V: Neuritic deposits of amyloid-β peptide in a subpopulation of central nervous system-derived neuronal cells. Mol. Cell Biol. 26, 4982-4997 (2006).
73. Muresan Z, Muresan V: Seeding neuritic plaques from the distance: a possible role for brainstem neurons in the development of Alzheimer's disease pathology. Neurodegenerative Dis. 5, 250-253 (2008).
74. Cai D, Leem JY, Greenfield JP et al.: Presenilin-1 regulates intracellular trafficking and cell surface delivery of β-amyloid precursor protein. J. Biol. Chem. 278, 3446-3454 (2003).
75. Naruse S, Thinakaran G, Luo JJ et al.: Effects of PS1 deficiency on membrane protein trafficking in neurons. Neuron 21, 1213-1221 (1998).
76. Wang R, Tang P, Wang P, Boissy RE, Zheng H: Regulation of tyrosinase trafficking and processing by presenilins: partial loss of function by familial Alzheimer's disease mutation. Proc. Natl Acad. Sci. USA 103, 353-358 (2006).
77. Lazarov O, Morfini GA, Pigino G et al.: Impairments in fast axonal transport and motor neuron deficits in transgenic mice expressing familial Alzheimer's disease-linked mutant presenilin 1. J. Neurosci. 27, 7011-7020 (2007). ■ Demonstrates that expression of presenilin 1 variants linked to familial forms of Alzheimer's disease in transgenic mice leads to impaired axonal transport of APP and Trk receptors, increased phosphorylation of cytoskeletal proteins, and motor neuron functional deficits.
78. Pigino G, Morfini G, Pelsman A, Mattson MP, Brady ST, Busciglio J: Alzheimer's presenilin 1 mutations impair kinesin-based axonal transport. J. Neurosci. 23, 4499-4508 (2003). ■ Identifies a mechanism whereby PS1 variants linked to familial forms of Alzheimer's disease lead to impairment of axonal transport; the mutant PS1 triggers activation of GSK3β, which phosphorylates the light chains of kinesin-1 and releases the motor from its cargoes.
79. Drubin DG, Kirschner MW: Tau protein function in living cells. J. Cell Biol. 103, 2739-2746 (1986).
80. Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM: Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J. Cell Biol. 156, 1051-1063 (2002).
81. Dixit R, Ross JL, Goldman YE, Holzbaur EL: Differential regulation of dynein and kinesin motor proteins by tau. Science 319, 1086-1089 (2008).
82. Seitz A, Kojima H, Oiwa K, Mandelkow EM, Song YH, Mandelkow E: Single-molecule investigation of the interference between kinesin, tau and MAP2c. EMBO J. 21, 4896-4905 (2002).
83. Vershinin M, Xu J, Razafsky DS, King SJ, Gross SP: Tuning microtubule-based transport through filamentous MAPs: the problem of dynein. Traffic 9, 882-892 (2008).
84. Khatoon S, Grundke-Iqbal I, Iqbal K: Brain levels of microtubule- associated protein tau are elevated in Alzheimer's disease: a radioimmuno-slot-blot assay for nanograms of the protein. J. Neurochem. 59, 750-753 (1992).
85. Wagner U, Utton M, Gallo JM, Miller CC: Cellular phosphorylation of tau by GSK-3β influences tau binding to microtubules and microtubule organisation. J. Cell Sci. 109(Pt 6), 1537-1543 (1996).
86. Lovestone S, Reynolds CH, Latimer D et al.: Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr. Biol. 4, 1077-1086 (1994).
87. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH: Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 402, 615-622 (1999).
88. Trojanowski JQ, Lee VM: Phosphorylation of paired helical filament tau in Alzheimer's disease neurofibrillary lesions: focusing on phosphatases. FASEB J. 9, 1570-1576 (1995).
89. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT: Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. 103, 26-35 (2002).
90. Velasco ME, Smith MA, Siedlak SL, Nunomura A, Perry G: Striation is the characteristic neuritic abnormality in Alzheimer disease. Brain Res. 813, 329-333 (1998).
91. Chee FC, Mudher A, Cuttle MF et al.: Over-expression of tau results in defective synaptic transmission in Drosophila neuromuscular junctions. Neurobiol Dis 20, 918-928 (2005).
92. Mudher A, Shepherd D, Newman TA et al.: GSK-3β inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol. Psychiatry 9, 522-530 (2004).
93. Morfini G, Pigino G, Mizuno N, Kikkawa M, Brady ST: Tau binding to microtubules does not directly affect microtubule-based vesicle motility. J. Neurosci. Res. 85, 2620-2630 (2007).
94. Yuan A, Kumar A, Peterhoff C, Duff K, Nixon RA: Axonal transport rates in vivo are unaffected by tau deletion or overexpression in mice. J. Neurosci. 28, 1682-1687 (2008).
95. King ME, Kan HM, Baas PW, Erisir A, Glabe CG, Bloom GS: Tau-dependent microtubule disassembly initiated by prefibrillar β-amyloid. J. Cell Biol. 175, 541-546 (2006).
96. Cruz JC, Kim D, Moy LY et al.: p25/cyclin-dependent kinase 5 induces production and intraneuronal accumulation of amyloid-β in vivo. J. Neurosci. 26, 10536-10541 (2006).
97. Cruz JC, Tseng HC, Goldman JA, Shih H, Tsai LH: Aberrant Cdk5 activation by p25 triggers pathological events leading to neurodegeneration and neurofibrillary tangles. Neuron 40, 471-483 (2003).
98. Falzone TL, Stokin GB, Lillo C et al.: Axonal stress kinase activation and tau misbehavior induced by kinesin-1 transport defects. J. Neurosci. 29, 5758-5767 (2009).
99. Garcia ML, Cleveland DW: Going new places using an old MAP: tau, microtubules and human neurodegenerative disease. Curr. Opin. Cell Biol. 13, 41-48 (2001).
100. Higuchi M, Lee VM, Trojanowski JQ: Tau and axonopathy in neurodegenerative disorders. Neuromolecular Med. 2, 131-150 (2002).
101. Bu G: Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 10, 333-344 (2009).
102. Tesseur I, Van Dorpe J, Bruynseels K et al.: Prominent axonopathy and disruption of axonal transport in transgenic mice expressing human apolipoprotein E4 in neurons of brain and spinal cord. Am. J. Pathol. 157, 1495-1510 (2000). ■ Demonstrates that neuronal expression in human APOE4 transgenic mice, a risk factor in Alzheimer's disease, leads to a complex pathology consistent with impaired axonal transport.
103. Tesseur I, Van Dorpe J, Spittaels K, Van den Haute C, Moechars D, Van Leuven F: Expression of human apolipoprotein E4 in neurons causes hyperphosphorylation of protein tau in the brains of transgenic mice. Am. J. Pathol. 156, 951-964 (2000).
104. Gotthardt M, Trommsdorff M, Nevitt MF et al.: Interactions of the low density lipoprotein receptor gene family with cytosolic adaptor and scaffold proteins suggest diverse biological functions in cellular communication and signal transduction. J. Biol. Chem. 275, 25616-25624 (2000).
105. Yamazaki H, Bujo H, Kusunoki J et al.: Elements of neural adhesion molecules and a yeast vacuolar protein sorting receptor are present in a novel mammalian low density lipoprotein receptor family member. J. Biol. Chem. 271, 24761-24768 (1996).
106. Andersen OM, Reiche J, Schmidt V et al.: Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc. Natl Acad. Sci. USA 102, 13461-13466 (2005).
107. Andersen OM, Schmidt V, Spoelgen R et al.: Molecular dissection of the interaction between amyloid precursor protein and its neuronal trafficking receptor SorLA/LR11. Biochemistry 45, 2618-2628 (2006).
108. Taira K, Bujo H, Hirayama S et al.: LR11, a mosaic LDL receptor family member, mediates the uptake of ApoE-rich lipoproteins in vitro. Arterioscler. Thromb. Vasc. Biol. 21, 1501-1506 (2001).
109. Muresan Z, Muresan V: The amyloid-β precursor protein is phosphorylated via distinct pathways during differentiation, mitosis, stress, and degeneration. Mol. Biol. Cell. 18, 3835-3844 (2007).
110. Kerschensteiner M, Schwab ME, Lichtman JW, Misgeld T: In vivo imaging of axonal degeneration and regeneration in the injured spinal cord. Nat. Med. 11, 572-577 (2005).
111. Misgeld T, Kerschensteiner M: In vivo imaging of the diseased nervous system. Nat. Rev. Neurosci. 7, 449-463 (2006).
112. Misgeld T, Kerschensteiner M, Bareyre FM, Burgess RW, Lichtman JW: Imaging axonal transport of mitochondria in vivo. Nat. Methods 4, 559-561 (2007).
113. Misgeld T, Nikic I, Kerschensteiner M: In vivo imaging of single axons in the mouse spinal cord. Nat. Protoc. 2, 263-268 (2007).
114. Duncan JE, Goldstein LS: The genetics of axonal transport and axonal transport disorders. PLoS Genet. 2, e124 (2006).
115. Dompierre JP, Godin JD, Charrin BC et al.: Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J. Neurosci. 27, 3571-3583 (2007).
116. Peris L, Wagenbach M, Lafanechere L et al.: Motor-dependent microtubule disassembly driven by tubulin tyrosination. J. Cell. Biol. 185, 1159-1166 (2009).
117. Qi Y, Wang JK, McMillian M, Chikaraishi DM: Characterization of a CNS cell line, CAD, in which morphological differentiation is initiated by serum deprivation. J. Neurosci. 17, 1217-1225 (1997).
118. Coleman M: Axon degeneration mechanisms: commonality amid diversity. Nat. Rev. Neurosci. 6, 889-898 (2005).